A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes ...

Novo Nordisk has become aware of several hundred units of Ozempic® (semaglutide) injection 1 mg distributed outside the Novo ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Several hundred units of counterfeit Ozempic (semaglutide 1mg injection) were seized by the Food and Drug Administration.

Eli Lilly sued four telehealth firms, but it is adopting a new legal strategy in its fight against compounded GLP-1s.

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

FDA Commissioner Marty Makary talks about his plans to revamp drug development and reduce ‘conflicts of interest’ between the ...

Furthermore, Novo Nordisk should earn important label expansions for some of its current medicines while developing new ones in other areas. Semaglutide is being tested in Alzheimer's disease. And the ...